PHARMACY **BENEFACT**

Number 1029 • May 2022

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 15 mg SR Capsule (DIN 02448327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **June 2, 2022.** The following grouping was removed from the Critical Supply Product List on **May 4, 2022.**

DEXTROAMPHETAMINE SULFATE

15 MG SUSTAINED-RELEASE CAPSULE

| 00002448327 | ACT DEXTROAMPHETAMINE SR | APH | \$ 0.9898 |
|-------------|--------------------------|-----|-----------|
| 00001924567 | DEXEDRINE | PAL | \$ 1.1637 |

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Tecnal-C 1/2 Capsule (DIN 00608181) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **June 6**, **2022**. The following grouping was removed from the Critical Supply Product List on **May 5**, **2022**.

BUTALBITAL / CODEINE PHOSPHATE / ASA / CAFFEINE

50 MG / 30 MG / 330 MG / 40 MG CAPSULE

| 00000608181 | TEVA-TECNAL-C 1/2 | TEV | \$ 2.0249 |
|-------------|-------------------|-----|-----------|
| 00000176206 | FIORINAL-C 1/2 | ARA | \$ 2.2544 |

Alberta Blue Cross has been advised by H.J. Sutton/Quality Home Products that the shortage for Ene-Med Rectal Enema (DIN 02231170) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **June 6, 2022.** The following grouping was removed from the Critical Supply Product List on **May 5, 2022.**

SODIUM PHOSPHATE / SODIUM ACID PHOSPHATE

10.4 G / 3.9 G RECTAL ENEMA

| 00002231170 | ENE-MED | HJS | \$ 1.9500 |
|-------------|-------------|-----|-----------|
| 0000009911 | FLEET ENEMA | Mſſ | \$ 3.8800 |

continued next page





continued from previous page

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Benzoyl Peroxide/Clinda Kit 5%/1% Topical Gel (DIN 02464519) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied and, as a result, the LCA price policy will be reapplied to the following grouping effective **June 6**, **2022**. The following grouping was removed from the Critical Supply Product List on **May 5**, **2022**.

CLINDAMYCIN PHOSPHATE / BENZOYL PEROXIDE

1 % / 5 % TOPICAL GEL

| 00002464519 | TARO-BENZOYL PEROXIDE/CLINDAMYCIN KIT | TAR | \$ 0.7422 |
|-------------|---------------------------------------|-----|-----------|
| 00002248472 | BENZACLIN | VCL | \$ 1.0442 |

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.1029 2022/05